Bone problems raised in several UK studies
30 August 2008. Related: Conference reports, Side effects.
Side effects
New-fill used to treat lipoatropy in feet
12 June 2008. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Tesamorelin (TH9507) reduces abdominal fat in patients with HIV-related lipodystrophy: 52 week results
2 December 2007. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Case report of efavirenz-associated nephrolithiasis
1 December 2007. Related: Side effects.
Yellow card reporting scheme for doctors and patients in the UK
1 December 2007. Related: Side effects.
30 cases of atazanavir-related kidney stones reported
3 July 2007. Related: Side effects.
Tenofovir and indinavir associated with increased risk of chronic renal failure in EuroSIDA study
3 July 2007. Related: Side effects.
Growth hormone release factor (TH9507) reduces central fat adiposity
4 April 2007. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Further insight into risk and management of cardiovascular disease (CVD) from D:A:D cohort: no additional benefit of metabolic syndrome diagnosis; new HIV-specific CVD risk equations; increasing uptake of lipid lowering drugs but low smoking cessation
4 April 2007. Related: Conference reports, Side effects.
d4T associated with significantly increased risk of type-2 diabetes mellitus
6 December 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Switching from PIs to NNRTIs has similar effect on TC/HDL ratio as use of lipid lowering drugs in the management of dyslipidaemia
6 December 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
The role of the metabolic syndrome in HIV
15 October 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Effect of lifestyle modification on risk factors for cardiovascular disease and metabolic syndrome
9 October 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Pioglitazone reduces peripheral lipoatrophy and improves adipokines without reducing visceral fat
9 October 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Tenofovir did not increase the incidence nephrotoxicity in limited numbers of HIV-positive patients using chemotherapy or HCV-coinfeced patients using ribavirin
9 September 2006. Related: Conference reports, Side effects, Cancer and HIV.
Use of HLA-B*5701 genetic testing to reduce abacavir hypersensitivity reactions
12 May 2006. Related: Conference reports, Side effects.
Regimen durability and toxicity in 36-month follow up on ART in Khayelitsha, South Africa
12 May 2006. Related: Conference reports, Side effects.
D:A:D study shows that PIs rather than NNRTIs drive the previously reported cardiovascular risk of combination antiretroviral therapy
25 March 2006. Related: Conference reports, Side effects.
Interventions for the management of lipodystrophy and metabolic complications
25 March 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Analysis of hepatic events in 2NN study by CD4 entry criteria, levels differences between nevirapine and efavirenz; excess hepatic events in once-daily nevirapine arm linked to single site in Thailand
11 February 2006. Related: Conference reports, Side effects.
Factors associated with sexual dysfunction in HIV patients
11 February 2006. Related: Conference reports, Side effects.
African-Americans in ACTG 5095 had shorter time to virologic failure and grade 3/4 side effects
10 February 2006. Related: Conference reports, Side effects.
Predictors of insulin resistance in first year of therapy
10 February 2006. Related: Conference reports, Side effects.
Monitoring side effects in resource limited countries
13 December 2005. Related: Conference reports, Side effects.
Uridine supplement reverses thymidine-induced lipoatrophy
13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Pravastatin increases limb fat in HIV-positive patients with hypercholesterolaemia
13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Evidence that facial fat can return after switching from either d4T or AZT, to abacavir or tenofovir
13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Niacin has beneficial effect on lipids but no reduction in abdominal fat
13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Gluteal implants used to replace lost buttock fat
13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Fatigue among HIV-positive patients in the era of highly active antiretroviral therapy
13 October 2005. Related: Side effects.
EMEA statement on metabolic and cardiovascular complications of antiretroviral therapy in HIV-infected patients
13 September 2005. Related: Side effects.
EMEA statement on use of antiretroviral treatment in HIV-patients with hepatic impairment and/or HBV/HCV co-infection
13 September 2005. Related: Side effects, Hepatitis coinfection.
Levels of efavirenz 10-fold above minimum target level despite coadministration with rifampicin
15 June 2005. Related: Conference reports, PK and drug interactions, Side effects.
Absolute risk is modest, but cumulative cardiovascular risk of HAART over five years is similar to ‘ever smoked’: new data on gender and age
18 April 2005. Related: Conference reports, Side effects.
Omega-3 supplement effective to reduce triglycerides
18 April 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Switch to tenofovir from AZT or d4T improves fat loss and improves lipid parameters compared to abacavir
18 April 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Continued use of a thymidine analogue may limit benefit from rosiglitazone when used to treat lipoatrophy
18 April 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
EuroSIDA shows HIV-HCV coinfected patients more likely to stop HAART because of side effects
29 March 2005. Related: Conference reports, Side effects.
Nucleoside analogue-related mitochondrial toxicity and link to lipoatrophy: effect of non-thymidine analogues abacavir and tenofovir
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Potential for uridine to treat mitochondrial toxicity: still only in vitro data
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
rHGH reduces central fat accumulation in adolescent lipodystrophy
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Endothelial dysfunction similar in ARV-experienced and -naive patients
31 January 2005. Related: Conference reports, Side effects.
Pravastatin improves lipid profiles but not endothelial function
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Treatment interruptions improve lipids within four weeks: IL-2 has no metabolic effect
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Improvement of lipids following switch to tenofovir
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Restorative treatments for HIV-associated lipoatrophy
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Side effects update: hypersensitivity, heart, bones
29 January 2005. Related: Conference reports, Side effects.
Vancouver researchers urge caution with combinations of lipid drugs
6 November 2004. Related: Side effects, Lipodystrophy and metabolic complications.
Three-year renal safety with tenofovir; cystatin may be a useful marker
6 September 2004. Related: Conference reports, Side effects.
Efficacy of acetyl-L-carnitine for antiretroviral toxic neuropathy
6 September 2004. Related: Side effects.
Oral uridine to treat mitochondrial toxicity
2 June 2004. Related: Side effects.
Phase II results show ThGRF could be safe, effective treatment for lipodystrophy, says company
2 June 2004. Related: Side effects, Lipodystrophy and metabolic complications.
Reversibility of lipoatrophy in HIV patients 2 years after switching from a thymidine analogue to abacavir
2 June 2004. Related: Side effects, Lipodystrophy and metabolic complications.
Diabetes and HIV and HCV; aging/HIV and diabetes
2 May 2004. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Eating grapefruit triggers statin-related rhabdomyolysis
2 May 2004. Related: PK and drug interactions, Side effects.
FDA panel recommends approval of New-Fill
2 May 2004. Related: Side effects, Lipodystrophy and metabolic complications.
Lipodystrophy regresses in three patients switched to atazanavir
2 May 2004. Related: Side effects, Lipodystrophy and metabolic complications.
Race affects absorption and clearance of efavirenz
3 April 2004. Related: Conference reports, PK and drug interactions, Side effects.
Update on peripheral neuropathy in HIV-infection
3 April 2004. Related: Conference reports, Side effects.
Smoking marijuana provides analgesic effect on HIV neuropathy
3 April 2004. Related: Conference reports, Side effects.
Two D:A:D updates: cardiovascular risk from HAART, and predictors of hypertension and changes in blood pressure
3 April 2004. Related: Conference reports, Side effects.
Low-dose rHGH maintains reductions in abdominal fat for 60 weeks
3 April 2004. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Rosiglitazone shows no benefit for lipoatrophy
2 April 2004. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Importance of dietary management in treating lipid disorders: soy diets may offer comparable effect as statins
3 February 2004. Related: Side effects, Lipodystrophy and metabolic complications.
Lower doses of d4T produce similar efficacy and reduced side effects
1 December 2003. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.